TapewireFind a company

person · Reporting owner

MCKENZIE DIANA

Disclosed activity across 4 companies

Tapewire entity
14718
SEC CIK
0001754648

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
METLIFE INCMET · Entity 488DirectorOctober 01, 2026October 05, 2026
VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875DirectorMay 01, 2026May 05, 2026
agilon health, inc.AGL · Entity 4698DirectorJune 02, 2026June 05, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

METLIFE INC

Report date October 01, 2026 · Filed October 05, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect25,929 Reported balance After 2026-10-01 transaction · row 1
1 source row

Row 1 · 2026-10-01 · Grant · Acquired 544 · Balance 25,929

F1: MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.

Filing footnotes · ownership attribution and instrument terms

F1: MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.

VERTEX PHARMACEUTICALS INC / MA

Report date May 01, 2026 · Filed May 05, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect2,378 Ending reported balance After 2026-05-01 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-05-01 · Grant · Acquired 943 · Balance 3,174

F1: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.

Row 2 · 2026-05-01 · Disposition to issuer · Disposed 796 · Balance 2,378

F2: Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2025, Ms. McKenzie deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units.

Deferred Stock UnitsSEC Table II · derivative / convertible securityDirect7,787.483 Reported balance After 2026-05-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2026-05-01 · Grant · Acquired 796 · Balance 7,787.483

F3: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F2: Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2025, Ms. McKenzie deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units.

Common StockSEC Table I · non-derivativeIndirectHeld in Trust207 Reported balance Holding disclosure · report date 2026-05-01 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 207

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.

F2: Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2025, Ms. McKenzie deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units.

F3: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

agilon health, inc.

Report date June 02, 2026 · Filed June 05, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect7,633 Reported balance After 2026-06-02 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-06-02 · Grant · Acquired 2,133 · Balance 7,633

F1: Restricted stock units that vest in full on June 2, 2027, subject to continued service as a director.

F2: The amount of securities beneficially owned following the reported transaction reflects the 1 for 25 reverse stock split of the Issuer's issued and outstanding common stock effective March 30, 2026.

F3: Includes restricted stock units.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock units that vest in full on June 2, 2027, subject to continued service as a director.

F2: The amount of securities beneficially owned following the reported transaction reflects the 1 for 25 reverse stock split of the Issuer's issued and outstanding common stock effective March 30, 2026.

F3: Includes restricted stock units.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Change Healthcare Inc.

Report date October 03, 2022 · Filed October 05, 2022

Section 16 reporting ended · disclosed 2022-10-05. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2022-10-03 transaction · row 1
1 source row

Row 1 · 2022-10-03 · Disposition to issuer · Disposed 40,706 · Balance 0

F1: On October 3, 2022, UnitedHealth Group Incorporated ("UnitedHealth Group") acquired Change Healthcare Inc. (the "Issuer") pursuant to that certain Agreement and Plan of Merger dated as of January 5, 2021 (the "Merger Agreement") by and among the Issuer, UnitedHealth Group and Cambridge Merger Sub Inc., a wholly owned subsidiary of UnitedHealth Group ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of UnitedHealth Group. At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Issuer (the "Common Stock") (other than certain excluded shares) automatically converted into the right to receive $25.75 per share in cash, without interest and less any applicable holding tax.

F2: At the Effective Time of the Merger, all deferred stock units of the Issuer automatically vested and were automatically converted into UnitedHealth Group deferred stock units calculated by taking the merger consideration of $25.75 per share of Common Stock and dividing it by the volume weighted average of the closing sale prices per share of UnitedHealth Group common stock on each of the five full consecutive trading days ending on and including the third business day prior to the Merger closing date and continue to be subject to the same terms and conditions (including settlement terms) as were applicable to the Issuer deferred stock units.

Filing footnotes · ownership attribution and instrument terms

F1: On October 3, 2022, UnitedHealth Group Incorporated ("UnitedHealth Group") acquired Change Healthcare Inc. (the "Issuer") pursuant to that certain Agreement and Plan of Merger dated as of January 5, 2021 (the "Merger Agreement") by and among the Issuer, UnitedHealth Group and Cambridge Merger Sub Inc., a wholly owned subsidiary of UnitedHealth Group ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of UnitedHealth Group. At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Issuer (the "Common Stock") (other than certain excluded shares) automatically converted into the right to receive $25.75 per share in cash, without interest and less any applicable holding tax.

F2: At the Effective Time of the Merger, all deferred stock units of the Issuer automatically vested and were automatically converted into UnitedHealth Group deferred stock units calculated by taking the merger consideration of $25.75 per share of Common Stock and dividing it by the volume weighted average of the closing sale prices per share of UnitedHealth Group common stock on each of the five full consecutive trading days ending on and including the third business day prior to the Merger closing date and continue to be subject to the same terms and conditions (including settlement terms) as were applicable to the Issuer deferred stock units.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
April 03, 2023 Filed Apr 5, 2023 21:04 UTC METLIFE INC MET · Entity 488 GrantCommon Stock 755 $57.97 $43,767.35
Disclosure

SEC source: 0001099219-23-000137 · wf-form4_168072865289910.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,257

F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.

Read SEC document
March 14, 2023 Filed Mar 16, 2023 20:36 UTC METLIFE INC MET · Entity 488 GrantCommon Stock 121 $59.07 $7,147.47
Disclosure

SEC source: 0001099219-23-000108 · wf-form4_167899895118897.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,502

F1 · kind: Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.

Read SEC document
February 28, 2023 Filed Mar 3, 2023 00:03 UTC METLIFE INC MET · Entity 488 GrantCommon Stock 31 $71.73 $2,223.63
Disclosure

SEC source: 0001099219-23-000089 · wf-form4_167780180660073.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,381

F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.

Read SEC document
February 17, 2023 Filed Feb 22, 2023 22:20 UTC agilon health, inc. AGL · Entity 4698 GrantOptions (Rights to Buy) · Derivative 11,104 $0.00 Strike: $22.79 $0.00
Disclosure

SEC source: 0001209191-23-011763 · doc4.xml · derivative · entry 2

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,104

Underlying: Common Stock · 11,104 shares

Expires 2033-02-17

F2 · derivative.exercise_date: Options that vest in three equal installments on each anniversary of February 17, 2023, subject to continued service as a director.

F2 · derivative.expiration_date: Options that vest in three equal installments on each anniversary of February 17, 2023, subject to continued service as a director.

Read SEC document
February 17, 2023 Filed Feb 22, 2023 22:20 UTC agilon health, inc. AGL · Entity 4698 GrantCommon Stock 1,078 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-011763 · doc4.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,078

F1 · shares: Restricted stock units that vest in full on February 17, 2024, subject to continued service as a director.

Read SEC document
January 13, 2023 Filed Jan 18, 2023 21:07 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 100.53 $298.42 $30,000.16
Disclosure

SEC source: 0001209191-23-003703 · doc4.xml · derivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,027.368

Underlying: Common Stock · 100.53 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

Read SEC document
January 03, 2023 Filed Jan 5, 2023 21:27 UTC METLIFE INC MET · Entity 488 GrantCommon Stock 520 $72.15 $37,518.00
Disclosure

SEC source: 0001099219-23-000027 · wf-form4_167295405353494.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,350

F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay 50% of non-management director retainer in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.

Read SEC document
December 14, 2022 Filed Dec 16, 2022 21:25 UTC METLIFE INC MET · Entity 488 GrantCommon Stock 94 $72.84 $6,846.96
Disclosure

SEC source: 0001099219-22-000203 · wf-form4_167122589949781.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,830

F1 · kind: Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife Inc. common stock that have become payable, but receipt of which the director has deferred.

Read SEC document
October 14, 2022 Filed Oct 18, 2022 20:25 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 101.072 $296.82 $30,000.19
Disclosure

SEC source: 0000899243-22-033743 · doc4.xml · derivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,926.838

Underlying: Common Stock · 101.072 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

Read SEC document
October 03, 2022 Filed Oct 5, 2022 20:28 UTC METLIFE INC MET · Entity 488 GrantCommon Stock 599 $62.62 $37,509.38
Disclosure

SEC source: 0001099219-22-000166 · wf-form4_166500172332928.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,735

F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay 50% of non-management director retainer fees in MetLife, Inc. common stock. The director deferred receipt under the MetLife Deferred Compensation Plan for Non-Management Directors.

Read SEC document
October 03, 2022 Filed Oct 5, 2022 20:31 UTC Change Healthcare Inc. CHNG · Entity 15437 Disposition to issuerCommon Stock 40,706 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-033009 · doc4.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · shares: On October 3, 2022, UnitedHealth Group Incorporated ("UnitedHealth Group") acquired Change Healthcare Inc. (the "Issuer") pursuant to that certain Agreement and Plan of Merger dated as of January 5, 2021 (the "Merger Agreement") by and among the Issuer, UnitedHealth Group and Cambridge Merger Sub Inc., a wholly owned subsidiary of UnitedHealth Group ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of UnitedHealth Group. At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Issuer (the "Common Stock") (other than certain excluded shares) automatically converted into the right to receive $25.75 per share in cash, without interest and less any applicable holding tax.

F2 · shares: At the Effective Time of the Merger, all deferred stock units of the Issuer automatically vested and were automatically converted into UnitedHealth Group deferred stock units calculated by taking the merger consideration of $25.75 per share of Common Stock and dividing it by the volume weighted average of the closing sale prices per share of UnitedHealth Group common stock on each of the five full consecutive trading days ending on and including the third business day prior to the Merger closing date and continue to be subject to the same terms and conditions (including settlement terms) as were applicable to the Issuer deferred stock units.

F1 · price: On October 3, 2022, UnitedHealth Group Incorporated ("UnitedHealth Group") acquired Change Healthcare Inc. (the "Issuer") pursuant to that certain Agreement and Plan of Merger dated as of January 5, 2021 (the "Merger Agreement") by and among the Issuer, UnitedHealth Group and Cambridge Merger Sub Inc., a wholly owned subsidiary of UnitedHealth Group ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of UnitedHealth Group. At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Issuer (the "Common Stock") (other than certain excluded shares) automatically converted into the right to receive $25.75 per share in cash, without interest and less any applicable holding tax.

F2 · price: At the Effective Time of the Merger, all deferred stock units of the Issuer automatically vested and were automatically converted into UnitedHealth Group deferred stock units calculated by taking the merger consideration of $25.75 per share of Common Stock and dividing it by the volume weighted average of the closing sale prices per share of UnitedHealth Group common stock on each of the five full consecutive trading days ending on and including the third business day prior to the Merger closing date and continue to be subject to the same terms and conditions (including settlement terms) as were applicable to the Issuer deferred stock units.

Read SEC document
September 14, 2022 Filed Sep 16, 2022 20:26 UTC METLIFE INC MET · Entity 488 GrantCommon Stock 98 $66.41 $6,508.18
Disclosure

SEC source: 0001099219-22-000144 · wf-form4_166335995531873.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,136

F1 · kind: Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.

Read SEC document
July 15, 2022 Filed Jul 19, 2022 20:33 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 95.081 $289.23 $27,500.28
Disclosure

SEC source: 0000899243-22-026342 · doc4.xml · derivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,825.766

Underlying: Common Stock · 95.081 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

Read SEC document
June 21, 2022 Filed Jun 23, 2022 20:14 UTC METLIFE INC MET · Entity 488 GrantCommon Stock 600 $62.53 $37,518.00
Disclosure

SEC source: 0000937834-22-000081 · wf-form4_165601528143631.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,038

F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay 50% of non-management director retainer fees in MetLife, Inc. common stock. The director deferred receipt under the MetLife Deferred Compensation Plan for Non-Management Directors.

Read SEC document
June 14, 2022 Filed Jun 16, 2022 20:29 UTC METLIFE INC MET · Entity 488 GrantCommon Stock 100 $61.86 $6,186.00
Disclosure

SEC source: 0000937834-22-000054 · wf-form4_165541132413217.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,438

F1 · kind: Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife Inc. common stock that have become payable, but receipt of which the director has deferred.

Read SEC document
May 01, 2022 Filed May 3, 2022 20:48 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 1,842 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-016338 · doc4.xml · derivative · entry 4

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,730.685

Underlying: Common Stock · 1,842 shares

Expires not disclosed

F2 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on the Issuer's board of directors, (ii) a change of control of the Issuer and (iii) Ms. McKenzie's disability or death.

F1 · price: Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2021, Ms. McKenzie deferred the receipt of 1,842 shares of common stock and received instead 1,842 deferred stock units pursuant to the Issuer's deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 1,842 shares of common stock in exchange for an equal number of deferred stock units.

F2 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on the Issuer's board of directors, (ii) a change of control of the Issuer and (iii) Ms. McKenzie's disability or death.

F2 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on the Issuer's board of directors, (ii) a change of control of the Issuer and (iii) Ms. McKenzie's disability or death.

Read SEC document
May 01, 2022 Filed May 3, 2022 20:48 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantCommon Stock 1,449 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-016338 · doc4.xml · nonDerivative · entry 2

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,884

F3 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.

Read SEC document
May 01, 2022 Filed May 3, 2022 20:48 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Disposition to issuerCommon Stock 1,842 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-016338 · doc4.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,435

F1 · price: Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2021, Ms. McKenzie deferred the receipt of 1,842 shares of common stock and received instead 1,842 deferred stock units pursuant to the Issuer's deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 1,842 shares of common stock in exchange for an equal number of deferred stock units.

Read SEC document
April 25, 2022 Filed Apr 27, 2022 21:07 UTC Change Healthcare Inc. CHNG · Entity 15437 GrantCommon Stock 7,658 $0.00 $0.00
Disclosure

SEC source: 0001062993-22-010883 · form4.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,706

F1 · shares: Represents the grant of deferred stock units that vest on April 25, 2023. The shares subject to the units will be issued to the Reporting Person after the Reporting Person's separation from service from the Issuer.

Read SEC document
April 14, 2022 Filed Apr 18, 2022 20:05 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 95.021 $289.41 $27,500.03
Disclosure

SEC source: 0000899243-22-014961 · doc4.xml · derivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 888.685

Underlying: Common Stock · 95.021 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

Read SEC document
April 01, 2022 Filed Apr 5, 2022 20:09 UTC METLIFE INC MET · Entity 488 GrantCommon Stock 532 $70.50 $37,506.00
Disclosure

SEC source: 0001099219-22-000094 · wf-form4_164918937600679.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,338

F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay 50% of non-management director retainer fees in MetLife, Inc. common stock. The director deferred receipt under the MetLife Deferred Compensation Plan for Non-Management Directors.

Read SEC document
March 14, 2022 Filed Mar 16, 2022 20:37 UTC METLIFE INC MET · Entity 488 GrantCommon Stock 87 $64.69 $5,628.03
Disclosure

SEC source: 0001099219-22-000074 · wf-form4_164746302367165.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,806

F1 · kind: Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife Inc. common stock that have become payable, but receipt of which the director has deferred.

Read SEC document
January 14, 2022 Filed Jan 19, 2022 21:21 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 119.265 $230.58 $27,500.12
Disclosure

SEC source: 0001209191-22-003717 · doc4.xml · derivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 793.664

Underlying: Common Stock · 119.265 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

Read SEC document
January 03, 2022 Filed Jan 5, 2022 21:38 UTC METLIFE INC MET · Entity 488 GrantCommon Stock 594 $63.23 $37,558.62
Disclosure

SEC source: 0000937834-22-000012 · wf-form4_164141870397495.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,720

F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay 50% of non-management director retainer fees in MetLife, Inc. common stock. The director deferred receipt under the MetLife Deferred Compensation Plan for Non-Management Directors.

Read SEC document
December 14, 2021 Filed Dec 16, 2021 21:33 UTC METLIFE INC MET · Entity 488 GrantCommon Stock 87 $60.80 $5,289.60
Disclosure

SEC source: 0001099219-21-000351 · wf-form4_163969039629364.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,126

F1 · kind: Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.

Read SEC document
October 15, 2021 Filed Oct 18, 2021 20:06 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 151.041 $182.07 $27,500.03
Disclosure

SEC source: 0001209191-21-060704 · doc4.xml · derivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 674.399

Underlying: Common Stock · 151.041 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

Read SEC document
October 01, 2021 Filed Oct 5, 2021 20:29 UTC METLIFE INC MET · Entity 488 GrantCommon Stock 600 $62.52 $37,512.00
Disclosure

SEC source: 0001099219-21-000322 · wf-form4_163346576952504.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,038

F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay 50% of non-management director retainer fees in MetLife, Inc. common stock. The director deferred receipt under the MetLife Deferred Compensation Plan for Non-Management Directors.

Read SEC document
September 14, 2021 Filed Sep 16, 2021 20:39 UTC METLIFE INC MET · Entity 488 GrantCommon Stock 82 $60.78 $4,983.96
Disclosure

SEC source: 0001099219-21-000294 · wf-form4_163182473735592.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,438

F1 · kind: Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.

Read SEC document
July 15, 2021 Filed Jul 16, 2021 20:06 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 138.889 $198.00 $27,500.02
Disclosure

SEC source: 0001209191-21-046901 · doc4.xml · derivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 523.358

Underlying: Common Stock · 138.889 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

Read SEC document
June 22, 2021 Filed Jun 24, 2021 18:26 UTC Change Healthcare Inc. CHNG · Entity 15437 GrantCommon Stock 7,136 $0.00 $0.00
Disclosure

SEC source: 0001062993-21-005917 · form4.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,048

F1 · shares: Represents the grant of deferred stock units that vests on June 22, 2022. The shares subject to the units will be issued to the Reporting Person after the Reporting Person's separation from service from the Issuer.

Read SEC document
June 15, 2021 Filed Jun 17, 2021 21:19 UTC METLIFE INC MET · Entity 488 GrantCommon Stock 589 $63.77 $37,560.53
Disclosure

SEC source: 0001099219-21-000248 · wf-form4_162396470105710.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,357

F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay 50% of non-management director retainer fees in MetLife, Inc. common stock. The director deferred receipt under the MetLife Deferred Compensation Plan for Non-Management Directors.

Read SEC document
June 14, 2021 Filed Jun 17, 2021 00:58 UTC METLIFE INC MET · Entity 488 GrantCommon Stock 73 $63.31 $4,621.63
Disclosure

SEC source: 0001099219-21-000216 · wf-form4_162389147905274.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,768

F1 · kind: Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.

Read SEC document
May 01, 2021 Filed May 4, 2021 20:18 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantCommon Stock 1,842 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-029865 · doc4.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,277

F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.

Read SEC document
April 15, 2021 Filed Apr 16, 2021 20:03 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 124.904 $220.17 $27,500.11
Disclosure

SEC source: 0001209191-21-026940 · doc4.xml · derivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 384.469

Underlying: Common Stock · 124.904 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

Read SEC document
April 01, 2021 Filed Apr 5, 2021 20:58 UTC METLIFE INC MET · Entity 488 GrantCommon Stock 609 $61.60 $37,514.40
Disclosure

SEC source: 0001099219-21-000161 · wf-form4_161765623642029.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,695

F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay 50% of non-management director retainer fees in MetLife, Inc. common stock. The director deferred receipt under the MetLife Deferred Compensation Plan for Non-Management Directors.

Read SEC document
March 15, 2021 Filed Mar 17, 2021 20:59 UTC METLIFE INC MET · Entity 488 GrantCommon Stock 69 $60.54 $4,177.26
Disclosure

SEC source: 0001099219-21-000130 · wf-form4_161601474458010.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,086

F1 · kind: Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.

Read SEC document
January 15, 2021 Filed Jan 19, 2021 21:41 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 121.086 $225.99 $27,364.23
Disclosure

SEC source: 0001209191-21-004031 · doc4.xml · derivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 259.565

Underlying: Common Stock · 121.086 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

Read SEC document
January 04, 2021 Filed Jan 5, 2021 21:32 UTC METLIFE INC MET · Entity 488 GrantCommon Stock 814 $46.08 $37,509.12
Disclosure

SEC source: 0001099219-21-000031 · wf-form4_160988226364740.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,017

F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay 50% of non-management director retainer fees in MetLife, Inc. common stock. The director deferred receipt under the MetLife Deferred Compensation Plan for Non-Management Directors.

Read SEC document
December 14, 2020 Filed Dec 16, 2020 22:07 UTC METLIFE INC MET · Entity 488 GrantCommon Stock 81 $45.84 $3,713.04
Disclosure

SEC source: 0001099219-20-000384 · wf-form4_160815645124539.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,203

F1 · kind: Represents imputed reinvestment of dividends on deferred shares in the reporting person's deferral account pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but that remain unpaid because payment has been deferred.

Read SEC document
October 15, 2020 Filed Oct 19, 2020 20:13 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 112.204 $222.81 $25,000.17
Disclosure

SEC source: 0001209191-20-055261 · doc4.xml · derivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 138.479

Underlying: Common Stock · 112.204 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

Read SEC document
October 01, 2020 Filed Oct 5, 2020 21:40 UTC METLIFE INC MET · Entity 488 GrantCommon Stock 1,007 $37.26 $37,520.82
Disclosure

SEC source: 0001099219-20-000350 · wf-form4_160193400989121.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,121

F1 · kind: The reporting person acquired these deferred shares under MetLife, Inc.'s non-management director compensation arrangements, which provide for 50% of non-management director retainer fees to be paid in MetLife, Inc. common stock, and the MetLife Deferred Compensation Plan for Non-Management Directors, under which directors may elect to defer receipt of such stock for a specified period of time.

Read SEC document
September 14, 2020 Filed Sep 16, 2020 20:25 UTC METLIFE INC MET · Entity 488 GrantCommon Stock 83 $38.84 $3,223.72
Disclosure

SEC source: 0001099219-20-000312 · wf-form4_160028794144053.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,114

F1 · kind: Represents imputed reinvestment of dividends on deferred shares in the reporting person's deferral account pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but that remain unpaid because payment has been deferred.

Read SEC document
July 15, 2020 Filed Jul 17, 2020 20:12 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 26.275 $292.77 $7,692.53
Disclosure

SEC source: 0001209191-20-042799 · doc4.xml · derivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26.275

Underlying: Common Stock · 26.275 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

Read SEC document
June 17, 2020 Filed Jun 19, 2020 20:41 UTC Change Healthcare Inc. CHNG · Entity 15437 GrantCommon Stock 14,486 $0.00 $0.00
Disclosure

SEC source: 0001062993-20-002930 · form4.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,912

F1 · shares: Represents the grant of deferred stock units that vests on June 17, 2021. The shares subject to the units will be issued to the Reporting Person after the Reporting Person's separation from service from the Issuer.

Read SEC document
June 16, 2020 Filed Jun 18, 2020 20:52 UTC METLIFE INC MET · Entity 488 GrantCommon Stock 970 $38.69 $37,529.30
Disclosure

SEC source: 0001099219-20-000275 · wf-form4_159251352832502.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,031

F1 · kind: The reporting person acquired these deferred shares under MetLife, Inc.'s non-management director compensation arrangements, which provide for 50% of non-management director retainer fees to be paid in MetLife, Inc. common stock, and the MetLife Deferred Compensation Plan for Non-Management Directors, under which directors may elect to defer receipt of such stock for a specific period of time.

Read SEC document
June 12, 2020 Filed Jun 16, 2020 21:00 UTC METLIFE INC MET · Entity 488 GrantCommon Stock 74 $37.45 $2,771.30
Disclosure

SEC source: 0001099219-20-000243 · wf-form4_159234119627548.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,061

F1 · kind: Represents imputed reinvestment of dividends on deferred shares in the reporting person's deferral account pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but that remain unpaid because payment has been deferred.

Read SEC document
June 03, 2020 Filed Jun 5, 2020 21:39 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantCommon Stock 1,435 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-034747 · doc4.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,435

F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.

Read SEC document
April 01, 2020 Filed Apr 2, 2020 21:23 UTC METLIFE INC MET · Entity 488 GrantCommon Stock 1,345 $27.90 $37,525.50
Disclosure

SEC source: 0001099219-20-000186 · wf-form4_158586257947262.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,987

F1 · kind: The reporting person acquired these deferred shares under MetLife, Inc.'s non-management director compensation arrangements, which provide for 50% of non-management director retainer fees to be paid in MetLife, Inc. common stock, and the MetLife Deferred Compensation Plan for Non-Management Directors, under which directors may elect to defer receipt of such stock for a specific period of time.

Read SEC document
March 13, 2020 Filed Mar 18, 2020 01:12 UTC METLIFE INC MET · Entity 488 GrantCommon Stock 63 $31.93 $2,011.59
Disclosure

SEC source: 0001099219-20-000156 · wf-form4_158449390692399.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,642

F1 · kind: Represents imputed reinvestment of dividends on deferred shares in the reporting person's deferral account pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but that remain unpaid because payment has been deferred.

Read SEC document
January 02, 2020 Filed Jan 6, 2020 21:51 UTC METLIFE INC MET · Entity 488 GrantCommon Stock 727 $51.62 $37,527.74
Disclosure

SEC source: 0001099219-20-000046 · wf-form4_157834745741825.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,579

F1 · kind: The Reporting Person acquired these Deferred Shares under MetLife, Inc.'s non-management Director compensation arrangements, which provide for 50% of non-management Director retainer fees to be paid in MetLife, Inc. common stock, and the MetLife Deferred Compensation Plan for Non-Management Directors, under which Directors may elect to defer receipt of such stock for a specific period of time.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.